PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryCurrent TOCInstructions for authors
 
J Neurol Neurosurg Psychiatry. Jul 1986; 49(7): 791–795.
PMCID: PMC1028904
Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome.
L Regeur, B Pakkenberg, R Fog, and H Pakkenberg
Abstract
During the last seven years 65 patients with Gilles de la Tourette's syndrome have been treated. Pimozide was used as the preferred drug because of our experience of treating other hyperkinesias which indicated fewer side-effects than with haloperidol. Of the 65 patients with Gilles de la Tourette's syndrome, 59 were treated with pimozide alone or in combination with tetrabenazine or clonidine. The dose ranges of pimozide were 0.5-9 mg per day. Eighty-one percent experienced a good clinical response without side-effects. The side-effects seen in our patients were sedation, gain in weight, depression, pseudoparkinsonism and akathisia; acute dystonic reactions, blurred vision, slurred speech and xerostomia did not occur. No cases of tardive dyskinesia were seen.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (646K), or click on a page image below to browse page by page.
Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of
BMJ Group